Novartis Ag (NVSEF) Common Equity (2016 - 2025)
Historic Common Equity for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $46.5 billion.
- Novartis Ag's Common Equity rose 549.11% to $46.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $46.5 billion, marking a year-over-year increase of 549.11%. This contributed to the annual value of $46.5 billion for FY2025, which is 549.11% up from last year.
- According to the latest figures from Q4 2025, Novartis Ag's Common Equity is $46.5 billion, which was up 549.11% from $44.8 billion recorded in Q3 2025.
- Over the past 5 years, Novartis Ag's Common Equity peaked at $67.8 billion during Q4 2021, and registered a low of $38.2 billion during Q3 2023.
- Its 5-year average for Common Equity is $50.2 billion, with a median of $48.7 billion in 2021.
- Per our database at Business Quant, Novartis Ag's Common Equity skyrocketed by 2197.12% in 2022 and then crashed by 3719.83% in 2023.
- Over the past 5 years, Novartis Ag's Common Equity (Quarter) stood at $67.8 billion in 2021, then fell by 12.38% to $59.4 billion in 2022, then fell by 21.33% to $46.8 billion in 2023, then decreased by 5.61% to $44.1 billion in 2024, then rose by 5.49% to $46.5 billion in 2025.
- Its Common Equity stands at $46.5 billion for Q4 2025, versus $44.8 billion for Q3 2025 and $42.1 billion for Q2 2025.